FATE

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs), which offer the potential for mass production and immediate availability. Fate Therapeutics has a pipeline of CAR T-cell and CAR NK-cell product candidates targeting various hematologic malignancies and solid tumors. The company's proprietary iPSC product platform is designed to overcome limitations of patient-specific cell therapies and enable more scalable manufacturing.